“…Additionally, animal models of this condition employing exposure to viral or bacterial immunostimulants provide valuable insights into the basis of schizophrenia-like disturbances [ 9 , 10 , 11 ]. One of the widely implemented approaches is maternal immune activation (MIA), produced by the prenatal administration of lipopolysaccharide (LPS) [ 12 , 13 , 14 , 15 , 16 ]. When considering a neurodevelopmental model of schizophrenia, MIA with LPS has been described in terms of various behavioural disturbances, including affected sensorimotor gating [ 12 , 17 , 18 ], anxiety-like behaviour [ 13 , 19 ], social interactions [ 15 ], exploratory or locomotor activity [ 19 , 20 , 21 ] and cognitive deficits [ 22 , 23 ] as well as diverse biochemical alterations in the brains of the offspring, including the CX3CL1-CX3CR1 and CD200-CD200R pairs, which are crucial in neuron–microglia communication [ 13 , 19 ].…”